Insulet Reports Second-Quarter Revenue Growth as Full-Year U.S. Omnipod Outlook Is Lowered

Insulet reported revenue growth for the second quarter, although the company lowered its full-year outlook for Omnipod in the U.S. market. Meanwhile, Zimmer Biomet increased its full-year outlook following a second-quarter earnings beat. Both healthcare companies provided updated financial projections based on their recent quarterly performance. While Insulet faces a revised downward trend for its specific product line, Zimmer Biomet shows positive momentum after exceeding its expected earnings targets for the period.